Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€639.00 | Pdkd | Hscpccds |
Sanofi: R&D Day Provides Robust Outlook on Pipeline Drugs Driving Long-Term Growth
We hold firm to our fair value estimate for Sanofi following the firm’s R&D day that highlighted 12 new potential blockbuster drugs. The solid innovation outlook reinforces Sanofi’s economic moat.